Seviteronel racemate (VT-464 racemate)
98%
- Product Code: 109600
CAS:
1375603-36-3
| Molecular Weight: | 399.34 g./mol | Molecular Formula: | C₁₈H₁₇F₄N₃O₃ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C, airtight, dry |
Product Description:
Seviteronel racemate, also known as VT-464 racemate, is primarily investigated for its potential in treating hormone-dependent cancers, particularly prostate cancer. It functions as an androgen biosynthesis inhibitor, targeting the CYP17A1 enzyme, which plays a critical role in the production of androgens. By inhibiting this enzyme, it reduces the levels of androgens that fuel the growth of prostate cancer cells. This mechanism makes it a promising candidate for patients with castration-resistant prostate cancer (CRPC), where traditional hormone therapies are no longer effective. Additionally, its ability to selectively inhibit CYP17A1 without significantly affecting cortisol production may offer a favorable safety profile compared to other treatments in this class. Research is ongoing to explore its efficacy, safety, and potential applications in other androgen-driven conditions.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | ฿49,896.00 |
+
-
|
Seviteronel racemate (VT-464 racemate)
Seviteronel racemate, also known as VT-464 racemate, is primarily investigated for its potential in treating hormone-dependent cancers, particularly prostate cancer. It functions as an androgen biosynthesis inhibitor, targeting the CYP17A1 enzyme, which plays a critical role in the production of androgens. By inhibiting this enzyme, it reduces the levels of androgens that fuel the growth of prostate cancer cells. This mechanism makes it a promising candidate for patients with castration-resistant prostate cancer (CRPC), where traditional hormone therapies are no longer effective. Additionally, its ability to selectively inhibit CYP17A1 without significantly affecting cortisol production may offer a favorable safety profile compared to other treatments in this class. Research is ongoing to explore its efficacy, safety, and potential applications in other androgen-driven conditions.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :